Philly Biotech Is On It

From our region’s epicenter of discovery, Greater Philadelphia researchers and companies are part of the global race to get a handle on COVID-19, including Biomeme, The Wistar Institute, and the newly formed Penn Center for Research on Coronaviruses and Other Emerging Pathogens (PENNCoV).

Article from The Philadelphia Citizen

Amicus opens UCity R&D tower, calls Philly the ‘Cradle of Cures’

The future of research and development, in rare diseases and beyond, is Philadelphia.

By moving its R&D team to University City this year, publically traded gene therapy company Amicus Therapeutics now calls the Greater Philadelphia region’s bustling cell and gene therapy ecosystem home.

Article from the Philadelphia Inquirer

Biotech company with U.S. headquarters in Montco raises $130 million in series B

The biotech company Immunocore, with its U.S. headquarters in Montgomery County, announced a $130 million Series B financing round to continue the development of T-cell receptor therapies.

Article from the Philadelphia Business Journal

Penn gene therapy spinout exceeds projections with $216M IPO

Penn Medicine spinout Passage Bio raised $216 million through an initial public offering to support the continued development of clinical trials for gene therapies to treat rare central nervous system disorders – exceeding expectations and proving that cell and gene therapies can thrive in the Greater Philadelphia region.

Article from the Philadelphia Business Journal

This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO

“This is not a bubble, it’s Philadelphia’s moment,” Steven Nichtberger, CEO of Cabaletta Bio offers his perspective on the region’s exponential growth as the epicenter of cell and gene therapy.

Article from the Philadelphia Inquirer

PACT 2019 Philadelphia Venture Report

PACT Philadelphia’s annual report ranks the region seventh in the country for VC funding after a record-setting $2.5 billion invested in 2019, fueled by a steady stream of life sciences deals and activity among cell and gene therapy and connected health companies.

Report from PACT

CRISPR’d Cells Show Promise in First U.S. Human Safety Trial

Last year, three cancer patients were treated with their own CRISPR-edited T cells as part of a groundbreaking U.S. trial to determine the safety of such a treatment.

The result? A promising breakthrough for gene editing.

Article from Wired

Biotech Tour: Inside the Newly Rehabbed Spring House Innovation Park

See inside the new Spring House Innovation Park, a soon-to-be hub of life sciences innovation housing companies like Anpac Bio – which will open its U.S. HQ and very first east coast clinical lab site on the campus.

Article from Philadelphia magazine

Philadelphia gene therapy startup plans $125M IPO

Another life sciences IPO for Greater Philadelphia: Gene therapy startup Passage Bio plans to go public via a $125 million IPO, to continue developing six gene therapy candidates for central nervous system diseases, including dementia.

Article from the Philadelphia Business Journal

A cell and gene therapy development center is taking 680K square feet at KOP’s Discovery Labs

New York-based Deerfield Management and King of Prussia’s The Discovery Labs will open the Center for Breakthrough Medicines, occupying 680,000 square feet of The Discovery Labs space to provide pre-clinical through commercial manufacturing of cell and gene therapies, adding to our rich ecosystem as a cell and gene therapy hub.

Article from